Mettler-Toledo (MTD) Stock Analysis
This is a peer-relative look at Mettler-Toledo (MTD): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.
Company Profile
| Profile Item | MTD |
|---|---|
| Name | Mettler-Toledo International Inc. |
| Country/Region | Switzerland |
| GICS Sector | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services |
| Market Capitalization | 34.25 billion USD |
| Currency | USD |
| Exchange | NYSE |
| Listing Date | November 14, 1997 |
| Security Type | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | Current stock: MTD | Industry group median |
|---|---|---|
| Total Return (1Y) | 21.58% | 24.62% |
| Total Return (3Y, Annualized) | 19.54% | 20.37% |
| Total Return (5Y, Annualized) | 2.36% | -4.02% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | Current stock: MTD | Industry group median |
|---|---|---|
| Volatility (1Y, Annualized) | 31.70% | 66.36% |
| Beta (5Y) | 1.15 | 0.93 |
| Max Drawdown (5Y) | -43.47% | -80.19% |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | Current stock: MTD | Industry group median |
|---|---|---|
| Sharpe Ratio (1Y) | 0.55 | 0.36 |
| Sortino Ratio (1Y) | 0.75 | 0.58 |
Profitability
ROE (TTM)
No usable ROE is available for Mettler-Toledo (MTD) this period, so the shareholder-equity return read is skipped.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
Group distribution
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- MTD
- --
Largest peers
- LLY
- 86.02%
- NVS
- 24.33%
- AZN
- 22.57%
- JNJ
- 20.02%
- MRK
- 5.06%
- MTD
- --
- ABBV
- --
Net Margin (TTM)
Mettler-Toledo (MTD) keeps 22.25% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.25%
Group distribution
- MTD
- 22.25%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Largest peers
- LLY
- 31.90%
- MTD
- 22.25%
- AZN
- 17.68%
- NVS
- 17.49%
- JNJ
- 16.20%
- ABBV
- 15.67%
- MRK
- 3.64%
Operating Margin (TTM)
Mettler-Toledo (MTD) turns 28.70% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
28.70%
Group distribution
- Max
- 83.12%
- MTD
- 28.70%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Largest peers
- LLY
- 53.66%
- ABBV
- 39.59%
- MRK
- 35.22%
- NVS
- 34.27%
- AZN
- 29.57%
- MTD
- 28.70%
- JNJ
- 25.74%
Profitability Metrics
| Metric | Current stock: MTD | Industry group median |
|---|---|---|
| ROE (TTM) | -- | -26.66% |
| ROA (TTM) | 20.09% | -12.50% |
| Net Margin (TTM) | 22.25% | 0.00% |
| Operating Margin (TTM) | 28.70% | 0.00% |
| Gross Margin (TTM) | 59.16% | 37.87% |
Growth
Revenue Growth
Mettler-Toledo (MTD) grew revenue 3.98%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.
EPS Growth
Mettler-Toledo (MTD) grew earnings per share 3.88%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.
Growth Metrics
| Metric | Current stock: MTD | Industry group median |
|---|---|---|
| Revenue Growth (YoY) | 3.98% | 11.45% |
| Revenue Growth (3Y CAGR) | 0.90% | 9.94% |
| EPS Growth (YoY) | 3.88% | 4.28% |
| EPS Growth (3Y CAGR) | 3.06% | 4.17% |
Financial Strength
Current Ratio (MRQ)
Mettler-Toledo (MTD) has current ratio of 1.10, in the tighter-liquidity quartile for its industry. The short-term cushion is thinner than most peers carry, even if the absolute comfort level still depends on the business model.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.10
Group distribution
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MTD
- 1.10
- Min
- 0.10
Largest peers
- LLY
- 1.39
- MRK
- 1.35
- MTD
- 1.10
- JNJ
- 1.02
- AZN
- 1.01
- NVS
- 0.88
- ABBV
- 0.87
Debt / Equity (MRQ)
Mettler-Toledo (MTD) has debt-to-equity ratio of 26.06, above the industry benchmark range. Debt sits unusually high against shareholders’ equity, leaving the balance sheet more exposed to rate, refinancing, or earnings shocks.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
26.06
Group distribution
- MTD
- 26.06
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Largest peers
- MTD
- 26.06
- NVS
- 1.29
- LLY
- 1.23
- MRK
- 1.20
- AZN
- 0.66
- JNJ
- 0.55
- ABBV
- --
Financial Strength Metrics
| Metric | Current stock: MTD | Industry group median |
|---|---|---|
| Current Ratio (MRQ) | 1.10 | 5.52 |
| Debt / Equity (MRQ) | 26.06 | 0.15 |
| Net Debt / EBITDA | 1.58 | 1.08 |
Dividends
Dividend Yield (TTM)
Mettler-Toledo (MTD) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- NVS
- 2.88%
- ABBV
- 2.40%
- MRK
- 2.29%
- JNJ
- 1.94%
- AZN
- 1.73%
- LLY
- 0.49%
- MTD
- 0.00%
Dividend Payout Ratio (TTM)
Mettler-Toledo (MTD) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
Group distribution
- MTD
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Largest peers
- MRK
- 343.43%
- ABBV
- 117.35%
- NVS
- 90.46%
- JNJ
- 80.12%
- AZN
- 45.38%
- LLY
- 21.71%
- MTD
- 0.00%
Dividend Metrics
| Metric | Current stock: MTD | Industry group median |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Mettler-Toledo (MTD) trades at P/E ratio of 37.38, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
37.38
Group distribution
- Max
- 85.34
- Q3
- 43.46
- MTD
- 37.38
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
Largest peers
- MRK
- 148.21
- ABBV
- 50.05
- LLY
- 43.95
- JNJ
- 41.92
- MTD
- 37.38
- NVS
- 31.02
- AZN
- 26.37
P/S Ratio (TTM)
Mettler-Toledo (MTD) trades at 8.16 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.16
Group distribution
- Max
- 58.18
- Q3
- 25.77
- MTD
- 8.16
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
Largest peers
- LLY
- 13.95
- MTD
- 8.16
- ABBV
- 7.80
- JNJ
- 6.69
- MRK
- 5.37
- NVS
- 5.35
- AZN
- 4.63
P/B Ratio (MRQ)
Mettler-Toledo (MTD) trades at 442.71 on P/B ratio, above the industry benchmark range. Investors are putting an unusually rich price on each dollar of book equity relative to peers.
MTD
Pharmaceuticals, Biotechnology & Life Sciences industry group
442.71
Group distribution
- MTD
- 442.71
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Largest peers
- MTD
- 442.71
- LLY
- 29.96
- NVS
- 8.25
- JNJ
- 8.16
- MRK
- 8.06
- AZN
- 5.59
- ABBV
- -112.34
Valuation Metrics
| Metric | Current stock: MTD | Industry group median |
|---|---|---|
| P/E Ratio (TTM) | 37.38 | 26.69 |
| P/S Ratio (TTM) | 8.16 | 7.30 |
| P/B Ratio (MRQ) | 442.71 | 3.25 |
| Free Cash Flow Yield (TTM) | 1.97% | -1.66% |